Form 4: Director George Morrow Receives NBIX Equity Grant

Neurocrine Biosciences Director George J. Morrow was granted 2,567 restricted stock units vesting in May 2027.

Summary

• Director George J. Morrow acquired 2,567 restricted stock units (RSUs) of Neurocrine Biosciences, Inc. (NBIX).
• The transaction occurred on May 27, 2026.
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• The grant is scheduled to vest in full on May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation grant for a board member.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

The RSUs are subject to a one-year vesting period, with full ownership expected on May 27, 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with long-term performance goals.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation packages for mid-to-large cap biotechnology companies.
• The one-year cliff vesting schedule is a common practice for annual director equity awards.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 2,567 RSUs on May 27, 2027.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Trading, Director Compensation, Restricted Stock Units